AMDA Pocket Guidelines

Dementia Depression Delirium

AMDA GUIDELINES App Bundle brought to you courtesy of AMDA and Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512442

Contents of this Issue

Navigation

Page 38 of 53

39 Adverse Drug Reactions (ADR) Cost Potential ADRs: • Altered cardiac conduction (QTc prolongation), blood dyscrasias, central nervous system (CNS) depression, dyslipidemia, extrapyramidal symptoms, hyperglycemia, neuroleptic malignant syndrome, orthostatic hypotension (falls), weight gain Oral: $$ Syringe: $$$$ Black Box Warning: Severe neutropenia Compared to the other antipsychotics, this agent has the highest risk of neutropenia: • Prior to initiation, obtain baseline CBC including the absolute neutrophil count (ANC) which must be ≥1,500/mcL. Monitor regularly. Potential ADRs: • Anticholinergic effects, orthostatic hypotension, bradycardia, syncope, falls, myocarditis, CNS depression, dyslipidemia, eosinophilia, extrapyramidal symptoms, hepatotoxicity, hyperglycemia, neuroleptic malignant syndrome, QTc prolongation, seizures, weight gain. $

Articles in this issue

view archives of AMDA Pocket Guidelines - Dementia Depression Delirium